All In Biotech

Drug Trial Radar · NCT03687255

Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections

A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis.

Last checked: Nov 19, 2026Latest source record: Mar 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,043 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,043

Actual

Start

Sep 24, 2018

Primary completion

Jan 30, 2020

Study completion Feb 15, 2020

Sponsor

Lead sponsor
AllecraIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Sep 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, randomized, double-blind, non-inferiority study of cefepime 2 g/AAI101 500 mg combination compared to piperacillin 4 g/tazobactam 500 mg in a population of adult patients with cUTI or AP. The study will be conducted in approximately 115 sites located in the EU, the US, Central, South America and South Africa.

Conditions

  • Urinary Tract Infections

Interventions

  • cefepime/AAI101 combinationDrug

    cefepime 2 g / AAI101 500 mg

  • Piperacillin/tazobactamDrug

    piperacillin 4 GM / tazobactam 500 MG

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients in the Microbiological Modified Intent to Treat (m-MITT) Population who achieve overall treatment success at Test Of Cure (TOC)Time frame: 7 days after EOT [±2 days] for patients receiving 7 days of treatment and 19 days after randomization [±2 days] for patients receiving more than 7 days of treatment.

Locations

24 sites in 19 countries. Site status is shown where the registry gives one.

  • St. Josephs Clinical Research

    Anaheim, California

  • Southbay Pharma Research

    Buena Park, California

  • Florida Urology Partners

    Tampa, Florida

  • Washington University School of Medicine

    St Louis, Missouri

  • Mercury Street Medical

    Butte, Montana

  • University of New Mexico Health Sciences Center

    Albuquerque, New Mexico

  • HIGA Dr Ramon Carrillo

    Buenos Aires, Argentina

  • Brest Regional Hospital

    Brest, Belarus

  • MHAT Rahila Angelova AD, Pernik

    Pernik, Bulgaria

  • University Hospital for Infectious Diseases "Dr. Fran Mihaljevic" Department for general infectious diseases

    Zagreb, Croatia

  • Tartu University Hospital

    Tartu, Estonia

  • Unimed Adjara - Kutaisi oncological centre

    Kutaisi, Georgia

  • Bugat Pal Korhaz

    Gyöngyös, Hungary

  • Uroklinika, LLC

    Riga, Latvia

  • Republican Siauliai caunty hospital

    Šiauliai, Lithuania

  • Centro Especializado en Investigación Clínica S.C.

    Boca del Río, Mexico

  • Clinica Internacional - Sede San Borja

    Lima, Peru

  • Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii

    Warsaw, Poland

  • Scientific Research Center Eco-Safety

    Saint Petersburg, Russia

  • Clinical Hospital Center Zvezdara

    Belgrade, Serbia

  • Interne oddelenie, Nemocnica Malacky, Nemocnicna a.s.

    Malacky, Slovakia

  • Clinical Projects Research

    Worcester, South Africa

  • Hospital del Mar, Department of Infectious Disease

    Barcelona, Spain

  • Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology

    Chernihiv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.